Shattuck Labs, Inc. (NASDAQ:STTK) Director Tyler Brous Acquires 3,000 Shares

Shattuck Labs, Inc. (NASDAQ:STTK) Director Tyler Brous purchased 3,000 shares of the stock in a transaction on Friday, June 28th. The shares were purchased at an average cost of $3.90 per share, with a total value of $11,700.00. Following the transaction, the director now owns 238,088 shares in the company, valued at approximately $928,543.20. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.

Shattuck Labs Stock Up 2.9 %

NASDAQ STTK opened at $3.86 on Monday. Shattuck Labs, Inc. has a twelve month low of $1.33 and a twelve month high of $11.76. The stock has a 50-day moving average of $7.70 and a 200 day moving average of $8.43.

Shattuck Labs (NASDAQ:STTK) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.08. The company had revenue of $1.15 million during the quarter, compared to analysts’ expectations of $0.30 million. Shattuck Labs had a negative return on equity of 64.85% and a negative net margin of 3,133.63%. The business’s revenue was up 2200.0% compared to the same quarter last year. Analysts predict that Shattuck Labs, Inc. will post -1.56 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have commented on the company. Citigroup lowered their price target on Shattuck Labs from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Monday, June 17th. HC Wainwright decreased their price objective on Shattuck Labs from $28.00 to $16.00 and set a “buy” rating for the company in a report on Thursday, June 20th. Needham & Company LLC decreased their price objective on Shattuck Labs from $12.00 to $8.00 and set a “buy” rating for the company in a report on Friday, June 14th. Finally, BTIG Research cut Shattuck Labs from a “buy” rating to a “neutral” rating in a report on Monday, June 17th.

Institutional Investors Weigh In On Shattuck Labs

Several large investors have recently bought and sold shares of STTK. Vanguard Group Inc. lifted its position in Shattuck Labs by 38.2% in the first quarter. Vanguard Group Inc. now owns 1,819,926 shares of the company’s stock valued at $16,270,000 after purchasing an additional 502,860 shares during the period. Franklin Resources Inc. acquired a new position in shares of Shattuck Labs during the 4th quarter worth approximately $11,663,000. Pinnacle Associates Ltd. raised its position in shares of Shattuck Labs by 13.9% during the 1st quarter. Pinnacle Associates Ltd. now owns 521,246 shares of the company’s stock worth $4,660,000 after purchasing an additional 63,800 shares during the last quarter. Monashee Investment Management LLC purchased a new stake in Shattuck Labs in the 4th quarter worth approximately $713,000. Finally, SG Americas Securities LLC grew its stake in Shattuck Labs by 4.8% in the 1st quarter. SG Americas Securities LLC now owns 39,377 shares of the company’s stock worth $352,000 after acquiring an additional 1,788 shares during the period. 58.74% of the stock is currently owned by hedge funds and other institutional investors.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.